Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Cited by (1,000)

Items 401–500 of 1,000

1. AXL inhibition improves BRAF-targeted treatment in melanoma
   Marta Nyakas, Karianne Giller Fleten, Mads Haugland Haugen, Nikolai Engedal, Christina Sveen, Inger Nina Farstad, Viví Ann Flørenes, Lina Prasmickaite, Gunhild Mari Mælandsmo, Kotryna Seip · 2022 · Scientific Reports
2. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
   Azusa Tanimoto, Tadaaki Yamada, Shigeki Nanjo, Shinji Takeuchi, Hiromichi Ebi, Kenji Kita, Kunio Matsumoto, Seiji Yano · 2014 · Oncotarget
3. Resistance to gefitinib and cross‐resistance to irreversible EGFR‐TKIs mediated by disruption of the Keap1‐Nrf2 pathway in human lung cancer cells
   Seong-Hee Park, Jae Hwan Kim, Eunsun Ko, Jeong‐Yub Kim, Myung Jin Park, Jong Min Kim, Hyemin Seo, Shibo Li, Ji-Yun Lee · 2018 · The FASEB Journal
4. A synergistic approach for management of lung carcinoma through folic acid functionalized co-therapy of capsaicin and gefitinib nanoparticles: Enhanced apoptosis and metalloproteinase-9 down-regulation
   Poonam Parashar, Chandra Bhushan Tripathi, Malti Arya, Jovita Kanoujia, Mahendra Vikram Singh, Abhishek Yadav, Gaurav Kaithwas, Shubhini Awasthi Saraf · 2018 · Phytomedicine
5. AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
   Almira Auyez, Emre Sayan, Marina V. Kriajevska, Eugene M. Tulchinsky · 2021 · Cancers
6. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
   Miriam Grazia Ferrara, Lorenzo Belluomini, Annafrancesca Smimmo, Marco Sposito, Alice Avancini, Diana Giannarelli, Michèle Milella, Sara Pilotto, Emilio Bria · 2023 · Critical Reviews in Oncology/Hematology
7. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
   Mikaella Vouri, Qian An, Matthew Birt, Geoffrey John Pilkington, Sassan Hafizi · 2015 · Oncotarget
8. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells
   Yuji Sakuma, Shoichi Matsukuma, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Shiro Koizume, Hironobu Sekiguchi, Haruhiro Saito, Haruhiko Nakayama, Yoichi Kameda, Tomoyuki Yokose et al. · 2013 · Laboratory Investigation
9. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
   Cristina Corno, Laura Gatti, Cinzia Lanzi, Nadia Zaffaroni, Diego Colombo, Paola Perego · 2016 · Current Medicinal Chemistry
10. Overcoming treatment resistance in cancer: Current understanding and tactics
    Guang Jer Wu, George Wilson, Jacob George, Christopher Liddle, Lionel Hebbard, Liang Qiao · 2016 · Cancer Letters
11. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells
    Youn Ju Lee, Taeho Lim, Min Su Han, Sun Hwa Lee, Suk‐Hwan Baek, Hong‐Yan Nan, ChuHee Lee · 2016 · Oncology Reports
12. A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
    Jonathan Rios‐Doria, Margaret F. Favata, Kerri Lasky, Patricia Feldman, Yvonne Y. C. Lo, Gengjie Yang, Christina Stevens, Xiaoming Wen, Sarita Sehra, Kamna Katiyar et al. · 2020 · Frontiers in Oncology
13. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
    Emma Karlsen, Sam L. Kahler, Joan Tefay, Shannon R. Joseph, Fiona Simpson · 2021 · Cells
14. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
    Francesca Zammarchi, Karin EG. Havenith, Simon Chivers, Paul Hogg, Francois Bertelli, Peter Tyrer, Narinder Janghra, Halla W. Reinert, John Anthony Hartley, Patrick H. van Berkel · 2022 · Molecular Cancer Therapeutics
15. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
    Sheena Bhalla, Farjana Jahan Fattah, Chul Woo Ahn, Jessica N. Williams, Alyssa Macchiaroli, Jonathan Padro, Meredith Pogue, Jonathan E. Dowell, William C. Putnam, Nigel William McCracken et al. · 2023 · Lung Cancer
16. Mismatch-Guided Deoxyribonucleic Acid Assembly Enables Ultrasensitive and Multiplex Detection of Low-Allele-Fraction Variants in Clinical Samples
    Dan Huang, Hui Deng, Juan Zhou, Guan A. Wang, Qian Lei, Chen Guo, Wanting Peng, Peng Liang, Chenlan Shen, Binwu Ying et al. · 2023 · Journal of the American Chemical Society
17. Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance
    Robert M. Jotte, David Robert Spigel · 2015 · Cancer Medicine
18. Minnelide: A Novel Therapeutic That Promotes Apoptosis in Non-Small Cell Lung Carcinoma In Vivo
    Ilona Roušalová, Sulagna Banerjee, Veena Sangwan, Kristen Evenson, Joel A. McCauley, Robert Arthur Kratzke, Selwyn Maurice Vickers, Ashok Kumar Saluja, Jonathan D’Cunha · 2013 · PLoS ONE
19. Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
    Junya Nakade, Shinji Takeuchi, Takayuki Nakagawa, Daisuke Ishikawa, Takako Sano, Shigeki Nanjo, Tadaaki Yamada, Hiromichi Ebi, Lu Zhao, Kazuo Yasumoto et al. · 2014 · Journal of Thoracic Oncology
20. Predictive biomarkers in precision medicine and drug development against lung cancer
    Bingliang Fang, Reza John Mehran, John Victor Heymach, Stephen G. Swisher · 2015 · 癌症：英文版
21. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer
    Lichao Sun, Joseph Burnett, Mari Gasparyan, Fangying Xu, Hui Jiang, Chang-Ching A. Lin, Ila Myers, Hasan Körkaya, Yajing Liu, Jamie N. Connarn et al. · 2016 · Oncotarget
22. Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells
    Yinzhong Lu, Jun Wan, Zhifeng Yang, Xiling Lei, Qi Niu, Lanxin Jiang, Willemijn M. Passtoors, Aiping Zang, Patrick C. Fraering, Fang Wu · 2016 · The FASEB Journal
23. Epithelial‐to‐mesenchymal transition and its role in EGFR‐mutant lung adenocarcinoma and idiopathic pulmonary fibrosis
    Yuji Sakuma · 2017 · Pathology International
24. Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
    Jing Xu, Jinghui Wang, Shucai Zhang · 2017 · Oncotarget
25. Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non‐small‐cell lung carcinoma harbouring EGFR T790M mutations
    Kaiyong Yang, Yan Chen, Jiaqian Zhou, Lin Ma, Yating Shan, Xiaoying Cheng, Yun Wang, Zhaoxin Zhang, Xiaojun Ji, Lili Chen et al. · 2019 · British Journal of Pharmacology
26. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
    Takeshi Jimbo, Mana Hatanaka, Takahiro Komatsu, Tomoe Taira, Kentaro Kumazawa, Naoyuki Maeda, Takashi Suzuki, Masahiro Ota, Noriyasu Haginoya, Takeshi Isoyama et al. · 2019 · Oncotarget
27. New insights into long non-coding RNAs in non-small cell lung cancer
    Ruifang Ye, Ruixiang Tang, Siyuan Gan, Rujia Li, Ying Cheng, Linlang Guo, Chao Zeng, Yanqin Sun · 2020 · Biomedicine & Pharmacotherapy
28. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis
    Neus Martínez‐Bosch, Helena Cristóbal, Mar Iglesias, Meritxell Gironella, Luís Barranco, Laura Visa, Domenico Calafato, Silvia Jiménez-Parrado, Julie Earl, Alfredo Carrato et al. · 2021 · EBioMedicine
29. Adaptive resistance to targeted therapies in cancer.
    Rafael Rosell, Niki Karachaliou, Daniela Morales-Espinosa, Carlota Costa, Miguel Ángel Molina‐Vila, Irene Sansano, Amaya Gascó, Santiago Viteri, Bartomeu Massutí, Jia Wei et al. · 2013 · Europe PMC (PubMed Central)
30. Tyro3, Axl, and Mertk Receptor Signaling in Inflammatory Bowel Disease and Colitis-associated Cancer
    Carla Vanina Rothlin, Jonathan A. Leighton, Sourav Ghosh · 2014 · Inflammatory Bowel Diseases
31. Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells
    Kyung-Chan Kim, ChuHee Lee · 2014 · Korean Journal of Physiology and Pharmacology
32. Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
    Pengfei Ma, Yujie Fu, Minjiang Chen, Ying Jing, Jie Wu, Ke Li, Ying H. Shen, Jianxin Gao, Mengzhao Wang, Xiaojing Zhao et al. · 2016 · Theranostics
33. Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity
    Kenichi Suda, Tetsuya Mitsudomi · 2015 · Archives of Toxicology
34. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
    Yanli Jin, Danian Nie, Juan Li, Xin Du, Yuhong Lu, Yangqiu Li, Chang Liu, Jingfeng Zhou, Jingxuan Pan · 2016 · Clinical Cancer Research
35. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL
    Ghada Abboud-Jarrous, Shivam Priya, Avi Maimon, Stuart L. Fischman, Mayan Cohen-Elisha, Rakefet Czerninski, Tal Burstyn‐Cohen · 2017 · Oncotarget
36. PTBP1-mediated regulation of AXL mRNA stability plays a role in lung tumorigenesis
    Chun-Yu Cho, Shih-Ying Chung, Shankung Lin, Jhy-Shrian Huang, Yen‐Lin Chen, Shih-Sheng Jiang, Li-Chun Cheng, Tsu-Hsiang Kuo, Jong‐Ding Lay, Ya-Yu Yang et al. · 2019 · Scientific Reports
37. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
    Soma Ghosh, Ilaria Marrocco, Yosef Yarden · 2020 · Advances in cancer research
38. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
    Claudia Cardone, Bernadette Blauensteiner, Verónica Moreno‐Viedma, Giulia Martini, Vittorio Simeon, Pietro Paolo Vitiello, Davide Ciardiello, Valentina Belli, Nunzia Matrone, Teresa Troiani et al. · 2020 · European Journal of Cancer
39. 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
    Santosh Kumar Upadhyay, Alissa R. Verone, Suzanne F. Shoemaker, Maochun Qin, Song Liu, Moray J. Campbell, Pamela A. Hershberger · 2013 · Cancers
40. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
    Rafael Rosell, Andrés Felipe Cardona, Oscar G. Arrieta, Andrés Aguilar, Masaoki Ito, Carlos Pedraz‐Valdunciel, Jordi Codony‐Servat, Mariacarmela Santarpía · 2021 · British Journal of Cancer
41. Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
    Pavel A. Levin, Rolf A. Brekken, Lauren A. Byers, John Victor Heymach, David E. Gerber · 2016 · Journal of Thoracic Oncology
42. Advances in targeted therapies and new promising targets in esophageal cancer
    Abbes Belkhiri, Wael M. El-Rifai · 2015 · Oncotarget
43. Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
    Shigeki Nanjo, Tadaaki Yamada, Hiroshi Nishihara, Shinji Takeuchi, Takako Sano, Takayuki Nakagawa, Daisuke Ishikawa, Lu Zhao, Hiromichi Ebi, Kazuo Yasumoto et al. · 2013 · PLoS ONE
44. Genetic modifiers of EGFR dependence in non-small cell lung cancer
    Tanaz Sharifnia, Victor Rusu, Federica Piccioni, Mukta Bagul, Marcin B. Imielinski, Andrew D. Cherniack, Chandra Sekhar Pedamallu, Bang Wong, Frederick Hugh Wilson, Levi A. Garraway et al. · 2014 · Proceedings of the National Academy of Sciences
45. Evaluation of Tyro3 Expression, Gas6-Mediated Akt Phosphorylation, and the Impact of Anti-Tyro3 Antibodies in Melanoma Cell Lines
    Stephen J. Demarest, Jennifer L. Gardner, Michelle C. Vendel, Eric Ailor, Suzanne T. Szak, Flora Huang, Adam Doern, Xiangyang Tan, Weixing Yang, Dorre A. Grueneberg et al. · 2013 · Biochemistry
46. Recent advances in the biology of human circulating tumour cells and metastasis
    Sofia Gkountela, Barbara Maria Szczerba, Cinzia Donato, Nicola Aceto · 2016 · ESMO Open
47. The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer
    Robert M. Gemmill, Patrick Nasarre, Joyce U. Nair-Menon, Federico Cappuzzo, Lorenza Maria Landi, Armida D’Incecco, Hidetaka Uramoto, Takeshi Yoshida, Eric B. Haura, Kent E. Armeson et al. · 2017 · Science Signaling
48. Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology
    Zhitong Bing, Zhiyuan Cheng, Danfeng Shi, Xinkui Liu, Jinhui Tian, Xiaojun Yao, Jingyun Zhang, Yongfeng Wang, Kehu Yang · 2018 · BMC Complementary and Alternative Medicine
49. Therapeutic aspects of the Axl/Gas6 molecular system
    Rossella Di Stasi, Lucía De Rosa, Luca Domenico D’Andrea · 2020 · Drug Discovery Today
50. Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases
    Ahmed M Abdelaal, Andrea L. Kasinski · 2021 · NAR Cancer
51. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
    Maicol Mancini, Yosef Yarden · 2015 · Seminars in Cell and Developmental Biology
52. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
    Toni Michel Brand, Mari Iida, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Bailey G. Flanigan, Andrew P. Stein, Ravi Salgia, Jana Rolff, Randall J. Kimple et al. · 2017 · Science Signaling · Retracted
53. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
    Kang Song, Ye Yuan, Yong Lin, Yanxia Wang, Jie Zhou, Qu‐Jing Gai, Lin Zhang, Min Mao, Xiao‐Xue Yao, Yan Qin et al. · 2018 · Europe PMC (PubMed Central)
54. Soluble AXL as a marker of disease progression and survival in melanoma
    Karine Flem Karlsen, Marta Nyakas, Inger Nina Farstad, Erin McFadden, Patrik Wernhoff, Kari Dolven Jacobsen, Viví Ann Flørenes, Gunhild Mari Mælandsmo · 2020 · PLoS ONE
55. Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors
    Samira Javadi, Mina Zhiani, Mir Ali Mousavi, Mojtaba Fathi · 2020 · European Journal of Cell Biology
56. Managing Resistance to EFGR- and ALK-Targeted Therapies
    Christine Marie Lovly, Puneeth Iyengar, Justin F. Gainor · 2017 · American Society of Clinical Oncology Educational Book
57. Gas6/AXL pathway: immunological landscape and therapeutic potential
    Xiaoqian Zhai, Dan Pu, Ru-Lan Wang, Jiabi Zhang, Yiyun Lin, Yuqing Wang, Ni Zhai, Xuan Peng, Qinghua Zhou, Lu Li · 2023 · Frontiers in Oncology
58. Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors
    Mi Ran Yun, Sun Min Lim, Seon‐Kyu Kim, Hun Mi Choi, Kyoung‐Ho Pyo, Seong Keun Kim, Ji Min Lee, You Won Lee, Jae Woo Choi, Hye Ryun Kim et al. · 2018 · Cancer Research
59. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer
    Shinji Nakamichi, Masahiro Seike, Akihiko Miyanaga, Mika Chiba, Fenfei Zou, Akiko Takahashi, Arimi Ishikawa, Shinobu Kunugi, Rintaro Noro, Kaoru Kubota et al. · 2018 · Oncotarget
60. Drug-adapted cancer cell lines as preclinical models of acquired resistance
    Martin Michaelis, Mark N. Wass, Jindrich Jr. Cinatl · 2019 · Cancer Drug Resistance
61. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy
    Min‐Shu Hsieh, Mong‐Wei Lin, Yi‐Hsuan Lee · 2019 · Lung Cancer
62. (−)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells
    Kozue Namiki, Pattama Wongsirisin, Shota Yokoyama, Motoi Sato, Anchalee Rawangkan, Ryo Sakai, Keisuke Iida, Masami Suganuma · 2020 · Scientific Reports
63. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
    Kenichi Suda, Leslie M. Rozeboom, Christopher J. Rivard, Hui Yu, Kim E. Ellison, Mary Ann Melnick, Trista K. Hinz, Daniel C. F. Chan, Lynn E. Heasley, Katerina A. Politi et al. · 2017 · Lung Cancer
64. Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer
    Fei Han, Jinxi He, Feng Li, Jiali Yang, Jun Wei, William Chi Shing Cho, Xiaoming Liu · 2015 · BioMed Research International
65. Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
    Kenichi Suda, Tetsuya Mitsudomi · 2014 · Progress in tumor research
66. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
    Luigi Formisano, Valentina D'Amato, Alberto Servetto, Simona Brillante, Lucia Raimondo, Concetta Di Mauro, Roberta Marciano, Roberta Clara Orsini, Sandro Cosconati, Antonio Randazzo et al. · 2015 · Oncotarget
67. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
    De‐Wei Wu, Tzu‐Chin Wu, Chih‐Yi Chen, Huei Lee · 2016 · Clinical Cancer Research
68. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
    Isabel Ben Batalla, Robert Erdmann, Heather G. Jørgensen, Rebecca Mitchell, Thomas Ernst, Gunhild v. Amsberg, Philippe Schafhausen, Janna L. Velthaus, Stephen H Rankin, Richard E. Clark et al. · 2016 · Clinical Cancer Research
69. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
    Hatim Husain, Michael D. Scur, Ayesha Murtuza, Nam Q. Bui, Brian D. Woodward, Razelle Kurzrock · 2017 · Molecular Cancer Therapeutics
70. Function of Axl receptor tyrosine kinase in non-small cell lung cancer (Review)
    Guoan Zhang, Meng Wang, Hongli Zhao, Wen Cui · 2017 · Oncology Letters
71. Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
    Masaru Watanabe, Hirotsugu Kenmotsu, Ryo Ko, Kazushige Wakuda, Akira Ono, Hisao Imai, Tetsuhiko Taira, Tateaki Naito, Haruyasu Murakami, Masato Abe et al. · 2018 · Cancer Science
72. Tumour biomarkers—Tracing the molecular function and clinical implication
    Jiahao Lin, Lie Ma, Di Zhang, Jiafeng Gao, Yipeng Jin, Zhihai Han, Degui Lin · 2019 · Cell Proliferation
73. Identifying transcriptional programs underlying cancer drug response with TraCe-seq
    Matthew T. Chang, Frances Shanahan, Thi Thu Thao Nguyen, Steven T. Staben, Lewis J. Gazzard, Sayumi Yamazoe, Ingrid E. Wertz, Robert Piskol, Yeqing Angela Yang, Zora D. Modrusan et al. · 2021 · Nature Biotechnology
74. Inhibitory role of Gas6 in intestinal tumorigenesis
    Reiko Akitake, Hiroshi Seno, Masato Nakatsuji, Yuto Kimura, Yuki Nakanishi, Takuto Yoshioka, Keitaro Kanda, Mayumi Kawada, Kenji Kawada, Yoshiharu Sakai et al. · 2013 · Carcinogenesis
75. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
    Seip, Kotryna, Fleten, Karianne G., Barkovskaya, Anna, Nygaard, Vigdis, Haugen, Mads H., Engesæter, Birgit Ø., Mælandsmo, Gunhild M., Prasmickaite, Lina · 2016 · Oncotarget
76. S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
    Hua Shen, Gao-Chan Wang, Xiang Li, Xin Quan Ge, Meng Wang, Zhumei Shi, Vikas Bhardwaj, Zixuan Wang, Ralph Zinner, Stephen C. Peiper et al. · 2020 · Oncogene
77. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Xueting Cai, Miao Jing, Rongwei Sun, Sainan Wang, Miguel Ángel Molina‐Vila, Imane CHAIB-OUKADOUR, Rafael Rosell, Peng Cao · 2021 · Pharmacological Research
78. AXL receptor tyrosine kinase as a therapeutic target in NSCLC
    Trever Grant Bivona, Ross A. Okimoto · 2015 · Lung Cancer Targets and Therapy
79. Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.
    Margarita Majem, Jordi Remón · 2013 · Europe PMC (PubMed Central)
80. Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer
    Adrian G. Sacher, Pasi Antero Janne, Geoffrey R. Oxnard · 2014 · Cancer
81. Molecular Pathways: Niches in Metastatic Dormancy
    Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, Yusuke Shiozawa · 2014 · Clinical Cancer Research
82. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer
    Jane Y. Zhao, Adriana Guerrero, Kevin Kelnar, Heidi J. Peltier, Andreas G. Bader · 2017 · Lung Cancer
83. Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition
    Giovanni Zito, Flores Naselli, Laura Saieva, Stefania Raimondo, Giovanna Calabrese, Claudio Guzzardo, Stefano Forte, Christian D. Rolfo, Rosalba Parenti, Riccardo Alessandro · 2017 · Scientific Reports
84. The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC).
    Meng Michelle Xu, Yiqun Xie, Songshi Ni, Hua Liu · 2015 · Europe PMC (PubMed Central)
85. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer
    Lifang Cheng, Lan-ying Gou, Ting Wei, Jian Zhang · 2020 · International Journal of Oncology
86. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
    Carminia Maria Della Corte, Umberto Malapelle, Elena Vigliar, Francesco Pepe, Giancarlo Troncone, Vincenza Ciaramella, Teresa Troiani, Erika Martinelli, Valentina Belli, Fortunato Ciardiello et al. · 2017 · Oncotarget
87. Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
    Samuel W. Brady, Jian Zhang, Daniel Seok, Hai Wang, Dihua Yu · 2013 · Molecular Cancer Therapeutics
88. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells
    Nitu Bansal, Prasun J. Mishra, Mark N. Stein, Robert S. DiPaola, Joseph R. Bertino · 2015 · Oncotarget
89. AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases
    Xiaoliang Wu, Wenjuan Ma, Qianghua Zhou, Haijuan Yan, Zuan-Fu Lim, Mayan Huang, Chuangzhong Deng, Xingsu Yu, Huifang Su, Satoshi Komo et al. · 2017 · Journal of Cancer Research and Clinical Oncology
90. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
    Bin-Chi Liao, Sebastian Griesing, James Chih‐Hsin Yang · 2019 · Therapeutic Advances in Medical Oncology
91. Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
    Mirna Swayden, Houssein Chhouri, Youssef Anouar, Luca Grumolato · 2020 · Cells
92. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance
    Blakely, Collin M., Bivona, Trever G. · 2012 · Cancer Discovery
93. Overcoming Resistance to Targeted Therapies in Cancer
    Keara L. Redmond, Anastasia Papafili, Mark Lawler, Sandra Van Schaeybroeck · 2015 · Seminars in Oncology
94. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
    Ji‐Youn Han, Ki Hyeong Lee, Sang‐We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung‐Ho Nam et al. · 2016 · Cancer Research and Treatment
95. Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer
    Jian Wu, Hongqiang Qin, Ting Li, Kai Cheng, Jiaqiang Dong, Miaomiao Tian, Na Chai, Hao Guo, Jinjing Li, Xin Yu You et al. · 2016 · Oncotarget
96. The role of phenotypic plasticity in the escape of cancer cells from targeted therapy
    Michael F. Emmons, Fernanda Faião‐Flores, Keiran S.M. Smalley · 2016 · Biochemical Pharmacology
97. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
    Natasha B. Leighl, Naiyer A. Rizvi, Lopes Gilberto de Lima, Wichit Arpornwirat, Charles M. Rudin, Alberto Chiappori, Myung‐Ju Ahn, Laura Q.M. Chow, Lyudmila A. Bazhenova, Arunee Dechaphunkul et al. · 2016 · Clinical Lung Cancer
98. Phosphatidylserine receptor-targeting therapies for the treatment of cancer
    Miso Park, Keon Wook Kang · 2019 · Archives of Pharmacal Research
99. Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
    Ksenija Asić · 2015 · Critical Reviews in Oncology/Hematology
100. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.
     Min Luo, Li-Wu Fu · 2014 · Europe PMC (PubMed Central)